Attorneys, Insurers Disagree With Manufacturers On Need For Clinical Evidence For MCIT Coverage
CMS says in its MCIT proposal that there’s no obligation for clinical studies, but AHIP is concerned about “clinical appropriateness” of devices
Both insurance group AHIP and the MedPAC group of Medicare advisors are insisting on CMS reimbursement for medical devices only supported by clinical trials. Industry attorneys weigh in.
You may also be interested in...
Industry groups were cool to parts of the CMS’s proposed Medicare Coverage of Innovative Technology (MCIT) rule dealing with commercial insurance coverage, as well as definitions used in the proposal.
The long-awaited proposed rule from the US Medicare agency would allow breakthrough products approved by the FDA to get reimbursed, while manufacturers continue to collect clinical and real-world data.
Health policy changes that President-elect Joe Biden will likely make during his four-year term include Medicaid expansion and a greater reliance on medical science, among others, experts say.